LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

• Status: Terminated
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

1. Male and female (post-menopausal or surgically sterile).

2. Age from 18 to 75 years inclusive.

3. Subjects with mild-to-moderate uncomplicated essential hypertension, with (not more than 2 in combination) or without prior treatment.

4. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 36 kg/m2.

Exclusion Criteria:

1. History or evidence of a secondary form of hypertension,

2. History of cardiovascular disease. Type 1 or type 2 diabetes mellitus.

3. Clinically significant valvular heart disease.

Other protocol-defined inclusion/exclusion criteria may apply